<DOC>
	<DOCNO>NCT01613573</DOCNO>
	<brief_summary>The purpose phase 1 study ass safety pharmacokinetics PEG somatropin , administer per week , compare daily use somatropin , evaluate safety possibility replace daily use somatropin .</brief_summary>
	<brief_title>Crossover Study Assess Safety Pharmacokinetic Pegylated Somatropin ( PEG Somatropin ) GHD Children</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<criteria>height less two standard deviation ( SD ) median height individual age height , growth velocity ( GV ) ≤4 cm/yr , GH peak concentration &lt; 7 ng/ml two different provocative test , bone age ( BA ; ≤9 year girls ≤10 year boys ) least 2 year less his/her chronological age ( CA ) ; preadolescence ( Tanner stage 1 ) CA &gt; 3 year ; height value record 3 month start GH treatment calculate pretreatment GV ; receive prior GH treatment stop GH treatment 4 week ; sign inform consent Patients Liver kidney dysfunction ( ALT &gt; upper limit normal 2 time , Cr &gt; upper limit normal ) , hepatitis B virus detection , antigenHBc , HBsAg HBeAg positive patient know highly allergic constitution allergic drug study Patients diabetes , serious cardiopulmonary , blood system , malignant tumor disease systemic infection immunocompromised mental disease Patients growth disorder , Turner syndrome , constitutional delay growth puberty , Laron syndrome , GH receptor deficiency , girl growth delay rule chromosomal abnormality Participated clinical trial drug 3 month Other case researcher consider unsuitable clinical trial</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>pegylated Somatropin</keyword>
	<keyword>PEG-GH</keyword>
	<keyword>Phase 1 study</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>